- Group says Genentech's (OTCQX:RHHBY) change to distribution of oncology drugs will negatively impact U.S. hospitals, clinics, and their patients.
- Says that while the distribution shift may improve Genentech's model, "it does so at the expend of the efficiencies, quality and safety within U.S. hospitals and clinics."
- Asks that Genentech "reverse this ill-advised decision."
- Source: Gautam Kollu
Hospital group goes after Genentech in full-page NYT ad
Recommended For You
About RHHBY Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| RHHBY | - | - |
| Roche Holding AG | ||